Hikma Pharmaceuticals (LON:HIK) Insider Mazen Darwazah Acquires 14,000 Shares

Hikma Pharmaceuticals PLC (LON:HIK) insider Mazen Darwazah purchased 14,000 shares of Hikma Pharmaceuticals stock in a transaction on Tuesday, September 16th. The stock was bought at an average price of GBX 1,603 per share, for a total transaction of £224,420.

Mazen Darwazah also recently made the following trade(s):

• On Thursday, August 7th, Mazen Darwazah acquired 200,000 shares of Hikma Pharmaceuticals stock. The stock was bought at an average cost of GBX 1,756 per share, for a total transaction of £3,512,000.

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock opened at GBX 1,625.53 on Thursday. The stock has a market capitalization of £3.60 billion, a PE ratio of 973.37, a PEG ratio of 2.38 and a beta of 0.41. The business’s 50 day simple moving average is GBX 1,840.10 and its 200 day simple moving average is GBX 1,951.99. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. Hikma Pharmaceuticals PLC has a one year low of GBX 1,595 and a one year high of GBX 2,360.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on HIK shares. JPMorgan Chase & Co. dropped their target price on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating on the stock in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,600 target price on shares of Hikma Pharmaceuticals in a research report on Thursday, August 7th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Hikma Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of GBX 2,627.50.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.